Actithera Inc.

Booth: (no booth)

Silver Sponsor

United States

Actithera is a biotechnology company developing next-generation radioligand therapies (RLTs) for solid tumors. Its proprietary discovery platform utilizes covalent chemistry to form irreversible bonds, extending tumor residency times to over 10 days while ensuring rapid systemic clearance. Actithera’s lead FAP-targeting candidate is expected to enter clinical trials in 2026.